androstenediol has been researched along with Encephalitis, Viral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carr, DJ; Daigle, J | 1 |
| Carr, DJ | 1 |
2 other study(ies) available for androstenediol and Encephalitis, Viral
| Article | Year |
|---|---|
Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production.
Topics: Androstenediol; Animals; Chemokine CCL2; Chlorocebus aethiops; Corticosterone; Encephalitis, Viral; Female; Herpes Simplex; Interferon Type I; Mice; Mice, Inbred ICR; RNA, Messenger; Vero Cells | 1998 |
Increased levels of IFN-gamma in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol.
Topics: Anabolic Agents; Androstenediol; Animals; Antineoplastic Agents; Chemokine CCL2; Chemokine CCL5; Chemokine CXCL10; Chemokines, CXC; Corticosterone; Cytokines; Encephalitis, Viral; Female; Flow Cytometry; Gene Expression; Herpes Simplex; Herpesvirus 1, Human; Injections, Subcutaneous; Interferon-gamma; Interleukin-12; Interleukin-2; Interleukin-6; Killer Cells, Natural; Mice; Mice, Inbred ICR; Survival Analysis; Trigeminal Ganglion; Viral Load | 1998 |